Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain
TerminatedNot applicableNCT00716807
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Patients with chronic masticatory muscle pain (i.e., pain greater than three months) or patients with burning mouth syndrome participate in this study. The aim of the study is to compare the pain killing effectiveness of nalbuphine, a narcotic pain killer, administered with either placebo or naloxone, a drug used to treat opiate overdose. A second goal is to determine if there are sex differences in these two drug regimens. Drugs will be administered with single-use intranasal spray devices. All participants will receive two sprays (one spray per nostril). One of the two sprays will be nalbuphine (5 mg). The other spray will be naloxone in half the participants and placebo in the other half.
Study details
- Official title
- Modeling Kappa Opioid Analgesic Mechanisms in Chronic Orofacial Pain Disorders
- Conditions
- Temporomandibular Joint Dysfunction Syndrome
- Burning Mouth Syndrome
- Interventions
- Drug: nalbuphine plus naloxone
- Drug: nalbuphine plus placebo
- Drug: nalbuphine plus naloxone
- Drug: nalbuphine plus placebo
- Sponsor
- University of California, San Francisco
- Start date
- 2008-01
- Primary completion
- 2010-06
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Clinical diagnosis of temporomandibular muscle pain OR * Clinical diagnosis of burning mouth syndrome * Pain duration: at least 3 months * Pain severity: 2 or greater on a 0 - 10 scale Exclusion Criteria: * No adverse reaction to study drugs * Not currently using narcotic analgesic drugs
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00716807